Introduction ONYX-015, or dl1520, is an adenovirus mutant that lacks the E1B 55K gene, and therefore cannot neutralize p53 during infection (Bischo et al., 1996) . In tumor cells that lack functional p53, E1B 55K should be dispensable, and, according to this hypothesis, ONYX-015 should replicate eciently in cancer cells and kill them. Furthermore, the virus should spread to neighboring tumor cells and continue spreading until it reaches normal cells. At this point, induction of p53 should prevent further viral spread. ONYX-015 would then have two therapeutic advantages: selectivity for tumor cells and ability to spread from the site of infection and thus amplify the viral dose. ONYX-015 entered Phase I clinical trials in April 1996, and is currently being evaluated in a pivotal Phase III trial, as well as many Phase I and Phase II indications. Results of clinical testing have been presented elsewhere (Khuri et al., 2000) . Brie¯y, ONYX-015 has proven safe, even at doses of 10*12 pfu/injection. Replication of virus has been seen in tumors from patients on trial, and responses have been observed that suggest strong clinical activity. In this brief review, I will focus on the issue of selectivity of ONYX-015 for replication based on the p53-pathway, and discuss recent data that address the ability of ONYX-015 to replicate in cancer cells that retain wildtype p53.
Infection of primary epithelial cells with ONYX-015 induces high levels of nuclear p53, through the action of E1a (Figure 1 , O'Shea and McCormick, in preparation) . ONYX-015 fails to replicate eciently in these cells. In contrast, infection with wild-type adenovirus degrades p53, through the concerted action of E1B 55K and the E4orf6 protein, and produces high titres of infectious virus. Induction of p53 by ONYX-015 in primary cells is thought to contribute to the failure of ONYX-015 to replicate eciently in these primary cells, although the precise mechanism of attenuation is not yet known. The fact that the E1B 55K protein has other functions complicates this interpretation, as discussed below.
ONYX-015 replicates in many tumor cell lines that express mutant p53 (Bischo et al., 1996; Harada and Berk, 1999) . Clearly, in these cells E1B 55K is dispensable for lytic growth. This observation is consistent with the hypothesis that E1B 55K should be dispensable in cells that lack p53, but formal proof of this has so far not been possible, since restoration of wild-type p53 in these cells causes extensive apoptosis. However, it is reasonable to assume that lack of p53 accounts for permissivity of these cells to ONYX-015, at least to some degree. However, we, and others, have reported that ONYX-015 also replicates in tumor cells that retain wild-type p53 (Goodrum and Ornelles, 1998; Heise et al., 1997; Rothmann et al., 1998; Turnell et al., 1999; Harada and Berk, 1999) . Furthermore, p53 appears to be functional in these tumor cells, as judged by induction of p53 activity following DNA damage (Ries et al., 2000a) . These observations are not consistent with an essential role for E1B 55K in the neutralization and destruction of p53 during lytic infection, and have raised the possibility that ONYX-015's selectivity is unrelated to p53 status. The discovery of the p14ARF pathway provides a potential solution to this paradox.
The p14ARF pathway p14ARF was identi®ed as an alternative reading from in the p16 INK4 locus, and was subsequently shown to bind and inhibit Mdm2. p14ARF (referred to as p19ARF in mouse cells) is induced by E1a, c-myc, Ras and E2F, providing a link between abnormal mitogenic signaling and p53 induction (de Stanchina et al., 1998; Sherr, 1998; Stott et al., 1998) . Such a link had been anticipated by the earlier discovery that these oncogenes promote p53-dependent apoptosis. Figure 1 shows the pathway that is thought to connect E2F to p53 via p14ARF. Equally important to this discussion is the report that radiation induces p53 in an ARFindependent manner (de Stanchina et al., 1998) .
Soon after the discovery of p14ARF, mice were made that fail to express this protein. One reason for this urgency related to the possibility that phenotypes previously ascribed to loss of p16 could in fact be due to loss of p14ARF. Indeed, loss of p14ARF resulted in high rates of spontaneous tumor formation, at frequencies similar to those seen in mice that have lost Oncogene (2000) 19, 6670 ± 6672 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: F McCormick expression of p53 (Sherr, 1998) . Examination of tumor cells growing in culture revealed that cells retaining wild-type p53 lost expression of p14ARF. On the other hand, cells with mutant p53 expressed high levels of p14ARF. Together these data suggest that most tumors lose p53 function, either by mutation in the p53 gene or loss of p14ARF expression (Stott et al., 1998) . Furthermore, a feedback loop somehow transmits signals from p53 to p14ARF in tumor cells, so that loss of p53 allows p14ARF accumulation. The basis of this feedback loop is not known, but may involve methylation of the p14ARF promoter.
The p14ARF pathway in adenovirus infected cells
Infection of primary human cells with wild-type adenovirus or ONYX-015 induces expression of p14ARF, as expected from prior reports of the role of E1a in this process. p53 accumulates to high levels in cells infected with ONYX-015, but is degraded in wild-type infected cells (Figure 1 ; O'Shea and McCormick, in preparation). In contrast, infection of p53-wild-type tumor cells leads to a modest accumulation of p53 protein following ONYX-015 infection, with no increase in p53 transcriptional activity (Ries et al., 2000a) . These tumor cells lack p14ARF, and these results are consistent with an essential role for p14ARF for ecient induction of p53 from E1a. However, p14ARF-independent pathways also exist, probably involving interaction of E1a with CBP/p300 (Chiou and White, 1997).
Replication of ONYX-015 in p53-wild-type tumor cells is not aected by the presence of p53, presumably because p53 transcriptional activity is tolerably low. When p53 levels are increased by transfection of a vector expressing p14ARF, replication of ONYX-015 is blocked, in a p53-dependent manner. Wild-type adenovirus is not aected by these high levels of p53. These data show that loss of p14ARF facilitates replication of ONYX-015 in p53-wild-type tumor cells. We believe that high levels of Mdm2 activity resulting from loss of the Mdm2 inhibitor p14ARF, suppresses p53 in these cells. Thus Mdm2 can substitute for E1B 55K in tumor cells that lack p14ARF: obviously it cannot do so in primary cells, because Mdm2 activity is blocked by p14ARF in these cells.
Recently, we have found another pathway that may contribute to ONYX-015 replication in p53-wild-type tumor cells. We observed that cells of this type, and, indeed, cancer cells that contain mutant p53, often express high levels of Mdm2 protein. This was surprising, as p53 has been considered the major transcriptional activator of Mdm2. Further analysis of these cells revealed that the Raf-MAP kinase pathway turns on transcription of Mdm2 mRNA in these cells, in a p53-independent manner. A responsive element was identi®ed in the P2 mdm2 promoter, just upstream from the p53-responsive promoter element (Ries, et al., 2000b) . These data explain an old observation, that Ras transformed cells are relatively resistant to radiation-induced killing, and predict that inhibitors of the Ras-MAP Kinase pathway could sensitize cells to killing by DNA damaging agents by elevating levels of p53. The precise contribution that this pathway makes to ONYX-015 replication is currently being investigated.
Two other categories of tumor cells need be considered, besides those that lack p14ARF. One category consists of cells expressing high-risk HPV E6 proteins, the other consists of tumor cells in which Mdm2 is ampli®ed. At ®rst sight, it may appear that expression of E6 would complement loss of E1B 55K, as both proteins target p53 for degradation (Howley et al., 1989) . However, E1a can induce accumulation of active p53 in cells such as HeLa that express E6. It is therefore possible that p53 may be induced during infection of HPV-positive tumor cells with ONYX-015 and that replication may be blocked under these circumstances. Indeed, Harada and Berk (1999) have reported that HeLa cells replicate ONYX-015 poorly relative to wild-type adenovirus. This is an important issue as ONYX-015 is being tested in squamous cell carcinoma of the head and neck, a disease with a relatively high frequency of HPV involvement, and may be a candidate for treatment of cervical carcinoma, in which HPV involvement is frequent.
Tumors in which high levels of Mdm2 suppress p53 may also seem like promising candidates for ONYX-015 therapy. However, E1a mediated induction of p14ARF in these cells during infection may inhibit Mdm2 and allow p53 accumulation. The precise outcome of such an infection is dicult to predict and needs to be tested experimentally.
Future prospects for improving ONYX-015
ONYX-015, dl1520, has a complete deletion of E1B 55K. This protein is known to have other functions that are necessary for ecient replication in some cell types. E1B 55K forms a complex with E4orf6 (Rubenwolf et al., 1997; Sarnow et al., 1984) and is involved in host mRNA nuclear export and shut-o of host protein synthesis (Babiss et al., 1985; Beltz and Flint, 1979) . This aspect of E1B 55K function appears to be unnecessary in tumor cells such as C33a, HCT116, A549 and others, in which ONYX-015 replicates E1B 55K almost as well as wild-type virus. However, in cells such as U20S, ONYX-015 is strongly attenuated, probably because other functions of the protein are essential. The molecular basis of these dierences between cell types is of great interest since it may re¯ect fundamental properties of tumor cells that we currently do not understand, and a better understanding could lead to more ecient viral replication. Another approach to this issue involves construction of E1B 55K or E4orf6 mutants that fail to target p53, but retain other useful functions of this complex intact. A search for such mutants is underway in Dr Shen's laboratory at Onyx Pharmaceuticals.
Clinical potency of ONYX-015 could be improved by one of several strategies. One takes advantage of the selective replication of ONYX-015 in tumor cells, and the selective expression of the late region of viral genome during replication. In this strategy, a transgene is inserted into ONYX-015 in a region of late gene expression. This transgene is expected to express selectively in cancer cells, and to express at high levels since the viral genome is ampli®ed through replication late in infection. Transgenes encoding prodrug converting enzymes and cytokines are under pre-clinical investigation. The approach has already proved promising by the demonstration that the HSV tk gene is more eective when expressed in a vector similar to ONYX-015 than in a non-replicating vector (Wildner et al., 1999) .
In addition to improving the potency of ONYX-015, attempts are underway to employ similar strategies taking advantage of the loss of other tumor suppressor functions in tumor cells. We believe that these approaches have the potential of providing considerable clinical bene®t to patients suering from many types of cancer, based on our understanding of the pathways that underlie this disease.
